RE:RE:RE:COVID-19: Expands program with McMaster after early successPerhaps this guess fast tracked much quicker than the other products in their pipeline...
"This would be a first as there are to date no therapeutics that have been demonstrated to relieve such undesirable immune response or avoid the resulting changes in the lung tissue which causes the breathing difficulties and ultimately death in severe COVID-19 cases. Also, given that YBG is already approved as a pharmaceutical additive, it is anticipated that this short term pre-clinical study will lead to approval for rapid human trials that could save lives within the current pandemic and beyond."